Nanobiotechnology and Nanomedicine Companies
Showing results 21 - 39 of 39 for suppliers of Biotechnology:
The company specializes in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using their proprietary technology.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.
nanoTherics Ltd was formed in August 2007 to exploit a novel gene transfection technology arising from biomedical research at Keele University and the University of Florida. The patented technology uses nanoparticles and magnetic fields to facilitate the delivery of foreign DNA into living cells.
nanoTools provides monoclonal and polyclonal antibody development services and products. Besides providing individually tailored custom solutions, the company develops, manufactures and markets phosphorylation and modification - state specific monoclonal antibodies and other innovative reagents for Signal Transduction and Alzheimer research, high throughput screening (HTS) and proteomics.
Nanovex Biotechnologies SL is an innovative technology-based spin-off from the University of Oviedo founded in 2014 that provides a wide range of services and products in the nanobiotechnology field.
NST is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents (ApoSense - a small molecule 'Interfacial Nanoswitch') based on the identification and targeting of cells undergoing apoptosis.
Orla has patented, developed and commercialized a technology which radically simplifies the way in which proteins are immobilised on surfaces.
A biotechnology company developing microfluidic technology (NanoAssemblr™) for the development and manufacture of nanomedicines.
Photon activaten nano drug delivery systems.
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Sirnaomics, Inc. is dedicated to becoming the leader in the RNAi technology focusing on (1) enhancement of the potency of active pharmaceutical ingredient (API) using multi-targeted small interfering RNA (siRNA) cocktail; (2) improvement of the API delivery in vivo using clinical viable synthetic polymeric and lipid nanoparticles.
The company uses a proprietary nanotechnology delivery systems designed to support the environment during stem cell culturing, harvesting, differentiation and post transplantation procedures.
SurModics® Synthetic ECM is a synthetic, stable, and scalable cell culture platform that provides an in vivo-like cell culture environment with its biomimetic extracellular matrix structure and surface. The technology produces results for cell research and cell-related applications. The nanofibrillar matrix utilizes Ultra-Web™ technology.
Tekmira is an emerging leader in the advancement of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (RNAi).
WaferGen Biosystems, Inc. is a leader in the development, manufacture and commercialization of next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries.
XDx is a molecular diagnostics company developing and commercializing practical applications built on insights from the Human Genome Project.
Zymeworks' core business focus is to develop a pipeline of enabling industrial enzymes for bio-processing and bio-product manufacturing. Zymeworks' core competency is in molecular simulations.